188 related articles for article (PubMed ID: 24691884)
1. [Tissue penetration of antibiotics. Does the treatment reach the target site?].
Lagler H; Zeitlinger M
Med Klin Intensivmed Notfmed; 2014 Apr; 109(3):175-81. PubMed ID: 24691884
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment].
Bellmann R
Med Klin Intensivmed Notfmed; 2014 Apr; 109(3):162-6. PubMed ID: 24643839
[TBL] [Abstract][Full Text] [Related]
3. [Pitfalls in determining resistance].
Rodloff AC
Med Klin Intensivmed Notfmed; 2014 Apr; 109(3):182-6. PubMed ID: 24696279
[TBL] [Abstract][Full Text] [Related]
4. [Antibiotic therapy: impact and resistance].
Weiler S; Corti N
Med Klin Intensivmed Notfmed; 2014 Apr; 109(3):167-74. PubMed ID: 24696278
[TBL] [Abstract][Full Text] [Related]
5. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
[TBL] [Abstract][Full Text] [Related]
6. [Strategies to avoid antibiotic resistance].
Kees MG
Med Klin Intensivmed Notfmed; 2013 Mar; 108(2):125-30. PubMed ID: 23344520
[TBL] [Abstract][Full Text] [Related]
7. Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.
Pea F
Clin Pharmacokinet; 2018 Feb; 57(2):177-189. PubMed ID: 28639230
[TBL] [Abstract][Full Text] [Related]
8. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
[TBL] [Abstract][Full Text] [Related]
9. A new paradigm for treating infections: "go hard and go home".
Lipman J; Boots R
Crit Care Resusc; 2009 Dec; 11(4):276-81. PubMed ID: 20001878
[TBL] [Abstract][Full Text] [Related]
10. Dose modulation: a new concept of antibiotic therapy in the critically ill patient?
Goncalves-Pereira J; Paiva JA
J Crit Care; 2013 Aug; 28(4):341-6. PubMed ID: 23337485
[TBL] [Abstract][Full Text] [Related]
11. [Adequate antibiotic therapy in intensive care units].
Engelmann L; Bellmann R
Med Klin Intensivmed Notfmed; 2014 Apr; 109(3):154-5. PubMed ID: 24652506
[No Abstract] [Full Text] [Related]
12. Pharmacokinetic aspects of beta-lactam antibiotic therapy in intensive care unit patients: A one-center experience with TDM.
Sadilová K; Halačová M; Černý D
Ceska Slov Farm; 2020; 69(1):17-23. PubMed ID: 32460506
[TBL] [Abstract][Full Text] [Related]
13. [Antibiotics: new and old drugs, rational prescription].
de With K; Stocker H; Borde J; Kern WV
Dtsch Med Wochenschr; 2012 Feb; 137(5):186-9. PubMed ID: 22278687
[No Abstract] [Full Text] [Related]
14. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients.
Aubron C; Corallo CE; Nunn MO; Dooley MJ; Cheng AC
Ann Pharmacother; 2011 Oct; 45(10):1193-8. PubMed ID: 21896920
[TBL] [Abstract][Full Text] [Related]
16. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
[TBL] [Abstract][Full Text] [Related]
17. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
Roberts JA; Lipman J
Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
[TBL] [Abstract][Full Text] [Related]
18. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
[TBL] [Abstract][Full Text] [Related]
19. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
20. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
